230,000 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Bought by LMR Partners LLP

LMR Partners LLP purchased a new stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 230,000 shares of the company's stock, valued at approximately $3,045,000.

Other institutional investors and hedge funds have also modified their holdings of the company. First Trust Advisors LP boosted its position in Takeda Pharmaceutical by 2.0% in the 4th quarter. First Trust Advisors LP now owns 3,240,932 shares of the company's stock valued at $42,910,000 after buying an additional 62,718 shares during the last quarter. Van ECK Associates Corp lifted its stake in shares of Takeda Pharmaceutical by 1.6% during the fourth quarter. Van ECK Associates Corp now owns 2,210,428 shares of the company's stock valued at $29,266,000 after acquiring an additional 35,192 shares during the period. Northern Trust Corp boosted its holdings in Takeda Pharmaceutical by 14.6% in the fourth quarter. Northern Trust Corp now owns 1,873,588 shares of the company's stock valued at $24,806,000 after acquiring an additional 238,161 shares during the last quarter. Summit Global Investments increased its position in Takeda Pharmaceutical by 75.5% in the fourth quarter. Summit Global Investments now owns 729,200 shares of the company's stock worth $9,655,000 after purchasing an additional 313,642 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in Takeda Pharmaceutical by 15,449.0% during the 4th quarter. BNP Paribas Financial Markets now owns 500,677 shares of the company's stock worth $6,629,000 after purchasing an additional 497,457 shares during the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Trading Up 0.8%

NYSE:TAK traded up $0.11 during mid-day trading on Friday, hitting $14.11. The company had a trading volume of 1,136,705 shares, compared to its average volume of 1,911,866. The firm has a market cap of $44.88 billion, a P/E ratio of 35.26, a P/E/G ratio of 0.24 and a beta of 0.26. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.58 and a fifty-two week high of $15.43. The business's fifty day moving average is $14.78 and its two-hundred day moving average is $14.00. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The business had revenue of $7.34 billion during the quarter, compared to analyst estimates of $8.02 billion. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Analyst Ratings Changes

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.